Research programme: small molecule HER-2 inhibitors - Cengent Therapeutics

Drug Profile

Research programme: small molecule HER-2 inhibitors - Cengent Therapeutics

Latest Information Update: 31 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cengent Therapeutics
  • Class Small molecules
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 31 Aug 2007 No development reported - Preclinical for Breast cancer in USA (unspecified route)
  • 01 Jul 2004 Compounds from this research programme are available for licensing (http://www.cengent.com)
  • 23 May 2003 GeneFormatics has merged with Structural Bioinformatics to form Cengent Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top